This report aims to assist event professionals across the globe in building an effective business case for leveraging technology within their strategic meetings management programs.
Building a Business Case for Strategic Meetings Management Technology
1. July 2012
Building a Business Case for Strategic
Meetings Management Technology
The complex spend category of strategic meetings and events management Analyst Insight
encompasses 9% of the average organization’s total budget. Within the next Aberdeen’s Insights provide the
two years, that figure is expected to increase by nearly 20%, reinforcing the analyst's perspective on the
need for organizations to leverage modern strategies for controlling research as drawn from an
spending on corporate events, driving visibility into several aspects of aggregated view of research
meetings management and ultimately driving more value out of strategic surveys, interviews, and
meetings and events. This Analyst Insight aims to assist organizations across data analysis
the globe in building an effective business case for leveraging technology
within their strategic meetings management programs.
A Contemporary View of Meetings and Events
Management
Nearly 70% of organizations view strategic meetings management as a
moderate-to-high priority function, proving that an enterprise’s events have
a direct link in achieving corporate business goals and objectives. With a
significant chunk of organizational finances spent on this category, it is
incumbent on internal stakeholders to leverage modern strategies and
solutions to better control the multifaceted nature of this function. As
detailed in Figure 1 (below), there are myriad priorities for the average
organization in managing their strategic meetings and events.
Figure 1: Current Priorities for Strategic Meetings Management
Source: Aberdeen Group, June 2012
This document is the result of primary research performed by Aberdeen Group. Aberdeen Group's methodologies provide for objective fact-based research and
represent the best analysis available at the time of publication. Unless otherwise noted, the entire contents of this publication are copyrighted by Aberdeen Group, Inc.
and may not be reproduced, distributed, archived, or transmitted in any form or by any means without prior written consent by Aberdeen Group, Inc.